CAMPONE, MARIA CAROLINA
CAMPONE, MARIA CAROLINA
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
2022 Campone, M.; De Laurentiis, M.; Zamagni, C.; Kudryavcev, I.; Agterof, M.; Brown-Glaberman, U.; Palacova, M.; Chatterjee, S.; Menon-Singh, L.; Wu, J.; Martin, M.
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
2022 Kuemmel, S.; Campone, M.; Loirat, D.; Lopez, R. L.; Thaddeus Beck, J.; de Laurentiis, M.; Im, S. -A.; Kim, S. -B.; Kwong, A.; Steger, G. G.; Adelantado, E. Z.; Duhoux, F. P.; Greil, R.; Kuter, I.; Lu, Y. -S.; Tibau, A.; Ozguroglu, M.; Scholz, C. W.; Singer, C. F.; Vega, E.; Wimberger, P.; Zamagni, C.; Couillebault, X. -M.; Fan, L.; Guerreiro, N.; Mataraza, J.; Sand-Dejmek, J.; Chan, A.
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0)
2022 De Laurentiis, M.; Borstnar, S.; Campone, M.; Warner, E.; Bofill, J. S.; Jacot, W.; Dent, S.; Martin, M.; Ring, A.; Cottu, P.; Lu, J.; Ciruelos, E.; Azim, H. A.; Chatterjee, S.; Zhou, K.; Wu, J.; Menon-Singh, L.; Zamagni, C.
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
2021 De Laurentiis, M.; Borstnar, S.; Campone, M.; Warner, E.; Bofill, J. S.; Jacot, W.; Dent, S.; Martin, M.; Ring, A.; Cottu, P.; Lu, J.; Ciruelos, E.; Azim, H. A.; Chatterjee, S.; Zhou, K.; Wu, J.; Menon-Singh, L.; Zamagni, C.
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial | 1.1 Articolo in rivista | 2022 | Campone, M.; De Laurentiis, M.; Zamagni, C.; Kudryavcev, I.; Agterof, M.; Brown-Glaberman, U.; Palacova, M.; Chatterjee, S.; Menon-Singh, L.; Wu, J.; Martin, M. | |
| A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer | 1.1 Articolo in rivista | 2022 | Kuemmel, S.; Campone, M.; Loirat, D.; Lopez, R. L.; Thaddeus Beck, J.; de Laurentiis, M.; Im, S. -A.; Kim, S. -B.; Kwong, A.; Steger, G. G.; Adelantado, E. Z.; Duhoux, F. P.; Greil, R.; Kuter, I.; Lu, Y. -S.; Tibau, A.; Ozguroglu, M.; Scholz, C. W.; Singer, C. F.; Vega, E.; Wimberger, P.; Zamagni, C.; Couillebault, X. -M.; Fan, L.; Guerreiro, N.; Mataraza, J.; Sand-Dejmek, J.; Chan, A. | |
| Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0) | 1.7 Commento, erratum, replica e simili | 2022 | De Laurentiis, M.; Borstnar, S.; Campone, M.; Warner, E.; Bofill, J. S.; Jacot, W.; Dent, S.; Martin, M.; Ring, A.; Cottu, P.; Lu, J.; Ciruelos, E.; Azim, H. A.; Chatterjee, S.; Zhou, K.; Wu, J.; Menon-Singh, L.; Zamagni, C. | |
| Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population | 1.1 Articolo in rivista | 2021 | De Laurentiis, M.; Borstnar, S.; Campone, M.; Warner, E.; Bofill, J. S.; Jacot, W.; Dent, S.; Martin, M.; Ring, A.; Cottu, P.; Lu, J.; Ciruelos, E.; Azim, H. A.; Chatterjee, S.; Zhou, K.; Wu, J.; Menon-Singh, L.; Zamagni, C. |